[{"orgOrder":0,"company":"Relation Therapeutics","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Funding","leadProduct":"Undisclosed","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Discovery Platform","graph3":"Relation Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Relation Therapeutics \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"3","companyTruncated":"Relation Therapeutics \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Relation Therapeutics","sponsor":"DCVC","pharmaFlowCategory":"D","therapeuticArea":"Musculoskeletal","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"","graph1":"Musculoskeletal","graph2":"Discovery","graph3":"Relation Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Musculoskeletal","amount2New":0.059999999999999998,"dosageForm":"","sponsorNew":"Relation Therapeutics \/ DCVC","highestDevelopmentStatusID":"2","companyTruncated":"Relation Therapeutics \/ DCVC"},{"orgOrder":0,"company":"Relation Therapeutics","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Preclinical","graph3":"Relation Therapeutics","amount2":0.31,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Trauma","amount2New":0.31,"dosageForm":"","sponsorNew":"Relation Therapeutics \/ GSK","highestDevelopmentStatusID":"4","companyTruncated":"Relation Therapeutics \/ GSK"}]

Find Clinical Drug Pipeline Developments & Deals by Relation Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PharmaVenue
                          Not Confirmed
                          PharmaVenue
                          Not Confirmed

                          Details : The collaboration aims to focus on the identification and validation of novel therapeutic targets for fibrotic diseases and osteoarthritis.

                          Brand Name : Undisclosed

                          Molecule Type : Undisclosed

                          Upfront Cash : $45.0 million

                          December 10, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                          Highest Development Status : Preclinical

                          Sponsor : GSK

                          Deal Size : $308.0 million

                          Deal Type : Collaboration

                          blank

                          02

                          PharmaVenue
                          Not Confirmed
                          PharmaVenue
                          Not Confirmed

                          Details : The net proceeds will enable Relation to advance its osteoporosis pipeline towards the clinicbe and to accelerate company's discovery of novel biology, targets and medicines.

                          Brand Name : Undisclosed

                          Molecule Type : Undisclosed

                          Upfront Cash : Undisclosed

                          March 14, 2024

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Musculoskeletal

                          Highest Development Status : Discovery

                          Sponsor : DCVC

                          Deal Size : $60.0 million

                          Deal Type : Financing

                          blank

                          03

                          PharmaVenue
                          Not Confirmed
                          PharmaVenue
                          Not Confirmed

                          Details : Project RE will focus on finding therapies to tackle viral entry and replication and is co-led between Mila (Quebec AI Institute) and Relation Therapeutics.

                          Brand Name : Undisclosed

                          Molecule Type : Undisclosed

                          Upfront Cash : Undisclosed

                          September 01, 2020

                          Lead Product(s) : Undisclosed

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Discovery Platform

                          Sponsor : Bill & Melinda Gates Foundation

                          Deal Size : $1.3 million

                          Deal Type : Funding

                          blank